Impact funds help fight dementia and antibiotic resistance

  20 February 2023

Marc Gitzinger started his “adventure” in antibiotics 12 years ago, co-founding Swiss start-up BioVersys to tackle deadly and drug-resistant pathogens, such as strains of tuberculosis. He has watched as even promising peer companies collapsed, and had to slow his own development programmes for fear of running out of money.

Further reading: Financial Times
Author(s): Financial Times
Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

LifeArc

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS





Ambassador Network

Join the AMR Insights Ambassador Network today!

Connect to over 550 AMR professionals and students in 60 countries!

More information
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!
Popup Plugin